- **Oragenics** has formed a strategic collaboration with **Receptor.AI** to utilize artificial intelligence for accelerating the development of pharmaceutical candidates targeting brain health conditions, aiming to expand its drug pipeline beyond ONP-002.  **[1174940_25b54e22467b41fb81ca68f5b0ff0a01]** 
- Its primary candidate, **ONP-002**, a fully synthetic neurosteroid, is currently in **Phase IIa clinical trials** in Australia, with plans to commence Phase IIb trials in the US.  **[1174940_25b54e22467b41fb81ca68f5b0ff0a01]** 
- Following the announcement of the partnership, Oragenics' shares rose by **2.30%** in premarket trading, reaching **$1.33**.  **[1174940_25b54e22467b41fb81ca68f5b0ff0a01]** 
- The company currently has **no revenue or sales**, reflecting its focus on research and development, and faces significant financial challenges.  **[1174940_25b54e22467b41fb81ca68f5b0ff0a01]**

ORAGENICS (OGEN)